Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ATTD 2022: Dexcom EVP Discusses New Portfolio, Research, Increasing The Market Of CGMs

Executive Summary

Chad Patterson, Dexcom’s executive vice president of global marketing and product management, talked to Medtech Insight about the premium continuous glucose monitor manufacturer’s plans for facing stiff competition over the coming years.

You may also be interested in...



UPDATED: JPM 2023: Baxter, Medtronic Pursue Simplification As Path To Growth

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations first day of the meeting.

Dexcom’s G7 Expands Globally After A Long Wait

Dexcom has expanded the availability of its G7 sensor to five new markets, including the UK and Germany. FDA approval in the US has been delayed by software changes.

Dexcom Works With FDA To Bring CGM To Hospitals After Pandemic

The FDA gave Dexcom and Abbott emergency permission to provide their continuous glucose monitoring systems to hospitals to be used by inpatients and hospital staff. Now the agency has granted Dexcom its breakthrough designation to accelerate the approval of Dexcom’s system for the in-hospital indication.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel